A Phase IIa Clinical Trial of 2-Iminobiotin for the Treatment of Birth Asphyxia in DR Congo, a Low-Income Country.

CONCLUSION: The present dosing regimen resulted in higher AUCs than targeted, necessitating a change in the dose regimen in future efficacy trials. No adverse effects that could be attributed to the use of 2-iminobiotin were observed. EudraCT number 2015-003063-12. PMID: 31960360 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31960360?dopt=Abstract

Source: Paediatric Drugs - January 20, 2020 Category: Pediatrics Authors: Biselele T, Bambi J, Betukumesu DM, Ndiyo Y, Tabu G, Kapinga J, Bola V, Makaya P, Tjabbes H, Vis P, Peeters-Scholte C Tags: Paediatr Drugs Source Type: research